Quotes 5-day view Delayed Nasdaq
05/30/2023
05/31/2023
06/01/2023
06/02/2023
06/05/2023
Date
325.3(c)
323.57(c)
323.62(c)
333.78(c)
334.42
Last
1 888 327
5 592 332
1 342 900
1 572 791
1 044 494
Volume
-1.42%
-0.53%
+0.02%
+3.14%
+0.19%
Change
Estimated financial data (e) (USD)
Sales 2023
9 768 M
-
-
Net income 2023
3 431 M
-
-
Net cash position 2023
14 031 M
-
-
P/E ratio 2023
25,3x
Yield 2023
-
Sales 2024
10 491 M
-
-
Net income 2024
3 883 M
-
-
Net cash position 2024
17 805 M
-
-
P/E ratio 2024
22,7x
Yield 2024
-
Capitalization
85 966 M
85 966 M
-
EV / Sales 2023
7,36x
EV / Sales 2024
6,50x
Nbr of Employees
4 800
Free-Float
99,5%
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (63.8%), Europe (30.3%) and other (5.9%).
Ratings of Vertex Pharmaceuticals Incorporated
All news about VERTEX PHARMACEUTICALS INCORPORATED
News in other languages on VERTEX PHARMACEUTICALS INCORPORATED
Analyst Recommendations on VERTEX PHARMACEUTICALS INCORPORATED
ETFs positioned on VERTEX PHARMACEUTICALS INCORPORATED ETFs and Trackers with Trackinsight
Vertex Pharmaceuticals Incorporated : Confirms growth trajectory
VERTEX PHARMACEUTICALS A very promising pipeline
Chart VERTEX PHARMACEUTICALS INCORPORATED
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends VERTEX PHARMACEUTICALS INCORPORATED
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
333,78 $
Average target price
372,14 $
Spread / Average Target
11,5%
Please enable JavaScript in your browser's settings to use dynamic charts.